View clinical trials related to Vaccination; Infection.
Filter by:The overall objective of the project is to identify the determinants of antibody-mediated immunity in infants born to mothers immunized during pregnancy. Using maternal pertussis immunization as a model, the project will identify key predictors and potential determinants of vaccine responses in pregnant women, of the transfer of maternal antibodies to the newborn and of vaccine responses in infants. A systems biology approach will be used to delineate pre-vaccination and post-vaccination cellular and molecular correlates of the immune response to pertussis immunization in peripheral blood and in breastmilk.
The purpose of this observational nationwide study is to evaluate the effects of three different COVID-19 vaccines for the outcome of different severities of incident COVID infection.
In 2017 the hepatitis B vaccine was added to the United Kingdom (UK) routine immunisation programme.An infection with the hepatitis B virus can cause severe inflammation of the liver and can cause severe long term liver damage.So that the hepatitis B vaccine can be introduced to the UK's childhood immunisation schedule without increasing the number of vaccine injections, the previously used '5-in-1' vaccine was replaced by a '6-in-1' vaccine. The '6-in-1' vaccine protects against diphtheria, tetanus, poliovirus, whooping cough (pertussis), hepatitis B and Haemophilus influenzae b (Hib). There are two licensed '6-in-1'vaccines available and these are called Infanrix hexa (6in 1(IH)and Vaxelis (6 in 1(V)). The Infanrix hexa vaccine is currently used routinely in the UK. We know from previous research studies that this vaccine works well with the other vaccines in the UK schedule, including the meningococcal B vaccine (MenB or Bexsero). At present we do not have this information for the Vaxelis vaccine, and it is important to check this as the components of Vaxelis are slightly different from Infanrix hexa. If we can show that immunisation with Vaxelis creates a similar response from the immune system to Infanrix hexa and is just as safe when given in the immunisation schedule along with the MenB vaccine, the National Health Service (NHS) in the UK will be able to use either vaccine for children in the UK. This will increase the flexibility and resilience of the UK's routine immunisation schedule.